Welcome to our dedicated page for GE HealthCare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on GE HealthCare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (Nasdaq: GEHC) announced on November 30, 2025 the unveiling of next‑generation SIGNA MRI technology and submitted 510(k) filings to the U.S. FDA seeking clearance. New systems include SIGNA Bolt (a 3.0T high‑field wide‑bore system) and SIGNA Sprint with Freelium (a 1.5T, purposefully helium‑free/ventless design with <1% helium usage). Both run on the AI‑driven SIGNA One workflow platform aimed at improving exam efficiency, patient setup, and imaging reconstruction. The announcement emphasizes sustainability, installation flexibility, and AI‑enabled workflow automation while noting regulatory clearance is pending.
GE HealthCare (Nasdaq: GEHC) announced FDA Premarket Authorization for Pristina Recon DL, a deep learning 3D mammography reconstruction application that enhances image sharpness, reduces artifacts, and preserves patient dose. The technology uses two sequential deep learning models plus iterative reconstruction and NVIDIA RTX acceleration to deliver fast, high-fidelity DBT images in the exam room. Clinical validation cited a 99.1% radiologist preference for overall image quality and improved detection of microcalcifications and masses. The feature is upgradable on Pristina Via and supports workflow and patient‑experience improvements.
GE HealthCare (Nasdaq: GEHC) introduced Genesis™ Radiology Workspace, a cloud-first radiology solution built to unify the user experience, streamline workflows, and enable diagnosticians to read from virtually anywhere.
The platform centers on Genesis™ View (510(k) pending; not available for sale in the United States), a zero-footprint viewer that offers high-performance 2D/3D visualization, embedded AI tools, FHIRcast interoperability, and direct access to Advanced Visualization apps. The suite integrates with GE HealthCare’s Genesis cloud portfolio and will be shown at RSNA 2025 (Nov. 30–Dec. 4) in Chicago, booth 7334.
GE HealthCare (Nasdaq: GEHC) declared a cash dividend of $0.035 per share for the fourth quarter of 2025. The dividend is payable on February 13, 2026 to shareholders of record as of January 9, 2026.
GE HealthCare (NYSE:GEHC) announced on November 24, 2025 the submission of a 510(k) to the U.S. FDA for Photonova™ Spectra, a next‑generation photon‑counting CT (PCCT) system built on GE HealthCare’s proprietary Deep Silicon detector technology. Photonova Spectra offers 8‑bin energy resolution, up to 50x more data versus conventional CT, a 0.23s rotation speed, wide detector coverage and UHD spectral imaging designed for neurology, oncology, musculoskeletal, thoracic and cardiac exams. The system is 510(k)‑pending, not CE marked and not available for sale in the U.S., Europe, Canada or other regions. GE HealthCare highlights NVIDIA partnership for accelerated computing and AI‑enabled reconstruction to support on‑demand spectral images and a one‑scan workflow.
GE HealthCare (Nasdaq: GEHC) agreed to acquire Intelerad for $2.3 billion in cash, aiming to create a cloud-first, AI-enabled enterprise imaging platform across inpatient and outpatient settings.
The deal is expected to close in H1 2026, accelerate GE HealthCare’s SaaS and recurring-revenue mix, and support the company’s goal to triple cloud-enabled offerings by 2028.
Intelerad is forecast to deliver ~$270 million revenue in the first full year (≈90% recurring) and an adjusted EBITDA margin >30%; GEHC expects immediate top-line and EBIT margin accretion, short-term slight EPS dilution due to financing, and a high-single-digit ROIC by year five.
GE HealthCare (Nasdaq: GEHC) announced that Cardiovascular Associates of America (CVAUSA) plans to expand use of FDA‑approved PET radiotracer Flyrcado (flurpiridaz F 18) across ~25 sites after a successful two‑week, 21‑patient pilot at Cardiovascular Medicine in Davenport, Iowa.
The network performs about 85,000 cardiac PET procedures annually, and GE highlighted new distribution support with CDL Nuclear Technologies and inclusion of flurpiridaz F 18 in a co‑published international procedure standard for cardiac PET MPI.
GE HealthCare (Nasdaq: GEHC) management will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 9:30 am GMT / 4:30 am ET / 3:30 am CT.
CFO Jay Saccaro will discuss business strategy and growth opportunities and will address recent questions about a competitor’s FDA approval of an X-ray contrast product; GE HealthCare does not expect that approval to have a material impact on its Pharmaceutical Diagnostics business. A live webcast will be available on the company investor website at the listed date and time.
GE HealthCare (Nasdaq: GEHC) said members of its management team will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 9:30 am GMT (4:30 am ET/3:30 am CT).
A live webcast will be available via the company's investor events page at https://investor.gehealthcare.com/news-events/events on the listed date and time.
GE HealthCare (Nasdaq: GEHC) reported third-quarter 2025 results for the period ended September 30, 2025. Revenues were $5.1 billion, up 6% reported and 4% organic year‑over‑year, with total company orders +6% organic and a book‑to‑bill of 1.06. Net income attributable to GE HealthCare was $446 million; diluted EPS was $0.98 and Adjusted EPS was $1.07. Adjusted EBIT margin was 14.8% and free cash flow was $483 million. The company raised the lower end of full‑year 2025 Adjusted EPS guidance to a range of $4.51 to $4.63 and reaffirmed other metrics while noting approximately $265 million of tariff impact to Adjusted EBIT and $0.45 to Adjusted EPS.